Anileridine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Anileridine
Anileridine2DCSD.svg
Clinical data
AHFS/Drugs.com Monograph
Routes of
administration
Tablets, injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding > 95%
Metabolism Hepatic
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C22H28N2O2
Molar mass 352.47 g/mol
3D model (JSmol)
Melting point 83 °C (181 °F)
 ☒N☑Y (what is this?)  (verify)

Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine is no longer manufactured in the US or Canada.[2] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate [3] It is also under international control per UN treaties.

Administration[edit]

As tablets or injection.[4]

Pharmacokinetics[edit]

Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[5] It is mostly metabolized by the liver.

References[edit]

  1. ^ U.S. Patent 2,897,204
  2. ^ "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Retrieved 28 July 2008. 
  3. ^ http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm
  4. ^ "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010. 
  5. ^ "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.